Our findings suggest that EZH2 repression of expression of the FOXO1 tumor suppressor can be targeted by EZH2 inhibitor as a monotherapy for PTEN-proficient cancers or in combination with taxane for treatment of PTEN-deficient prostate cancers. The gene discussed is PTEN; the disease is Familial prostate cancer.